Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M. (October 2022)